Trans Genic Inc. (2342.T)
JPY 181.0
(0.56%)
JPY 181.0
(0.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.81 Billion JPY | -16.22% |
| 2022 | 4.55 Billion JPY | 19.62% |
| 2021 | 3.8 Billion JPY | -2.01% |
| 2020 | 3.88 Billion JPY | 23.04% |
| 2019 | 3.15 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.81 Billion JPY | 26.32% |
| 2023 Q1 | 4.26 Billion JPY | -6.21% |
| 2023 Q4 | 3.81 Billion JPY | -13.08% |
| 2023 Q3 | 4.38 Billion JPY | 0.53% |
| 2023 Q2 | 4.36 Billion JPY | 2.22% |
| 2023 FY | 3.81 Billion JPY | -16.22% |
| 2022 Q4 | 4.55 Billion JPY | 8.37% |
| 2022 FY | 4.55 Billion JPY | 19.62% |
| 2022 Q3 | 4.19 Billion JPY | 3.87% |
| 2022 Q2 | 4.04 Billion JPY | 0.0% |
| 2021 FY | 3.8 Billion JPY | -2.01% |
| 2020 FY | 3.88 Billion JPY | 23.04% |
| 2019 FY | - JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -17.42% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -5912.421% |
| GNI Group Ltd. | 26.34 Billion JPY | 85.527% |
| Linical Co., Ltd. | 10.3 Billion JPY | 63.003% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -545.969% |
| Soiken Holdings Inc. | 697.02 Million JPY | -446.974% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -26.212% |
| AnGes, Inc. | 2.78 Billion JPY | -36.681% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -642.306% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 95.782% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -979.21% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -131.078% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -707.134% |
| CanBas Co., Ltd. | 91.98 Million JPY | -4044.601% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -248.621% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -370.782% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -542.132% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 10.379% |
| PeptiDream Inc. | 29.11 Billion JPY | 86.905% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -572.998% |
| Ribomic Inc. | 155.8 Million JPY | -2346.929% |
| SanBio Company Limited | 2.25 Billion JPY | -69.078% |
| Healios K.K. | 11.28 Billion JPY | 66.219% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -1417.313% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -933.208% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -1478.709% |
| StemRIM | 187 Million JPY | -1938.789% |
| CellSource Co., Ltd. | 677.73 Million JPY | -462.537% |
| FunPep Company Limited | 189.32 Million JPY | -1913.763% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -538.664% |
| Stella Pharma Corporation | 1.44 Billion JPY | -164.097% |
| TMS Co., Ltd. | 97.68 Million JPY | -3802.728% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -4066.979% |
| Cuorips Inc. | 200.96 Million JPY | -1797.152% |
| K Pharma,Inc. | 209.13 Million JPY | -1723.011% |
| Takara Bio Inc. | 11.42 Billion JPY | 66.615% |
| ReproCELL Incorporated | 741.03 Million JPY | -414.49% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -315.439% |
| StemCell Institute Inc. | 3.85 Billion JPY | 0.985% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -319.684% |
| CellSeed Inc. | 301.04 Million JPY | -1166.426% |